No Data
No Data
Zhuhai Rundu Pharmaceutical (002923.SZ): Products such as Fluconazole Powder for Oral Suspension and Itraconazole Hydrochloride Tablets have not yet been included in the national centralized procurement.
Zhuhai Rundu Pharmaceutical (002923.SZ) stated during an investor relations event on September 19th that the company continues to monitor the pharmaceutical procurement policy and reforms in the pharmaceutical industry, improve its independent research and development system, optimize its product structure and services. Among the varieties that the company has obtained consistency evaluation and registration approval for generic drugs, products such as fluconazole oral suspension and itopride hydrochloride tablets have not yet been included in the national procurement, but they have certain competitiveness in the market and are expected to have a positive impact on the company's performance in the future.
Rundu Pharmaceutical Gets European Regulators' Nod for Losartan Potassium
Zhuhai Rundu Pharmaceutical (002923.SZ): The active pharmaceutical ingredient of losartan potassium has obtained a CEP certificate.
Zhuhai Rundu Pharmaceutical (002923.SZ) announced in a statement that the company recently received a notice from the European Directorate for the Quality of Medicines & HealthCare (EDQM)...
Zhuhai Rundu Pharmaceutical: Summary of Half-Year Report in 2024.
Zhuhai Rundu Pharmaceutical: Half-year report for the year 2024.
On July 31st, the number of shareholders holding shares after the market of Zhuhai Rundu Pharmaceutical (002923.SZ) was 14,198.
On August 7th, Gelunhui reported that as of after-market on July 31st, 2024, there were 14,198 shareholder accounts for Zhuhai Rundu Pharmaceutical on the investor interaction platform.
No Data
No Data